Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development
Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ended March 31, 2022.
